← ANALYST RATINGS · TIPRANKS
Braveheart Bio, Inc. (BRVE): analyst forecast and price target
Analyst consensus
Moderate Buy2 Buy0 Hold0 Sell
Ratings of 2 analysts in the last 3 months · top analysts only12-month forecast
Based on 2 price targets given in the last 3 months, the average target is $48.00, the highest $48.00, the lowest $48.00. The average is +156.5% from the last price of $18.71.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| James Condulis★★★★★★★★★★#3810 · hits 56% · avg +8.9% | Stifel Nicolaus | $45.00 | Buy | +140.5% | Reiterated | 01.10.26on TipRanks 10:15 | +5.8%next day −1.4% · 5 days −12.1% | ↗ |
| Salveen Richter★★★★★★★★★★#967 · hits 51% · avg +12.5% | Goldman Sachs | $48.00 | Buy | +156.5% | Reiterated | 08.09.26on TipRanks Sep 9 07:50 | +10.5%next day −1.2% · 5 days −8.1% | ↗ |
| Olivia Brayer★★★★★★★★★★#9632 · hits 39% · avg −1.2% | Cantor Fitzgerald | $40.00 | Buy | +113.8% | Initiated | 31.08.26on TipRanks 06:20 | −6.8%next day +3.7% · 5 days +15.5% | ↗ |
| Tyler Van Buren★★★★★★★★★★#42 · hits 64% · avg +38.8% | TD Cowen | — | Buy | — | Initiated | 31.08.26on TipRanks 05:55 | −6.8%next day +3.7% · 5 days +15.5% | ↗ |
| Name not given | — | $48.00 | Buy | +156.5% | Initiated | 31.08.26on TipRanks 05:05 | −6.8%next day +3.7% · 5 days +15.5% | ↗ |
| No ratings for this filter. | ||||||||
Every rating the collector has kept for the last 12 months, including the earlier ones of the same analyst. Latest of each analyst
Best analysts covering Braveheart Bio, Inc.
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $45.25 at a price of $20.20 (+124.0%); now: $45.25 at $18.71 (+141.8%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 1 | 2 | 2 |
| Buy | 0 | 0 | 0 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Best top-analyst consensus in the sector · General
About Braveheart Bio, Inc.
- CEO: Travis Murdoch
- Employees: 49
- One Letterman Drive, Building A, Suite A4-300, San Francisco, CA, 94129, US
- www.braveheart.bio
Braveheart Bio, Inc. engages in the development of therapeutics to treat hypertrophic cardiomyopathy. Its lead product candidate is BHB-1839 which is a small-molecule cardiac myosin inhibitor. The company was founded on May 13,2024 and is headquartered in San Francisco, CA.
Data from the stock’s TipRanks forecast page, read 87 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗